EI
COGT icon

Ellevest Inc’s Cogent Biosciences COGT Stock Holding History

Ellevest Inc’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-36
Closed -$388 – 611
2023
Q1 		$388 Buy
+36
New +$460 ﹤0.01% 1706
2022
Q4 		– Sell
-7
Closed – – 1870
2022
Q3 		$0 Buy
+7
New +$96 ﹤0.01% 1648

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ellevest Inc's COGT Position: Q2 2023 in Review

Ellevest Inc sold out of Cogent Biosciences (COGT) in Q2 2023, closing a stake of 36 shares — an estimated $388 sold.

Ellevest Inc first reported a position in COGT in Q3 2022 and held it in 2 quarters. The position peaked at $388 in Q1 2023. 136 funds tracked by Wall St. Rank hold COGT as of Q2 2023.

  • Ellevest Inc reported no remaining Cogent Biosciences position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 36 Cogent Biosciences shares in Q2 2023, an estimated $388.
  • Ellevest Inc first reported a position in Cogent Biosciences in Q3 2022 and held it in 2 quarters.
  • Ellevest Inc's Cogent Biosciences position peaked at $388 in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.